-
1 Comment
Carl Zeiss Meditec AG is currently in a long term uptrend where the price is trading 28.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.8.
Carl Zeiss Meditec AG's total revenue sank by 0.2% to $369M since the same quarter in the previous year.
Its net income has increased by 19.3% to $46M since the same quarter in the previous year.
Finally, its free cash flow grew by 53.4% to $40M since the same quarter in the previous year.
Based on the above factors, Carl Zeiss Meditec AG gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | DE0005313704 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Beta | 1.55 |
|---|---|
| Market Cap | 4B |
| PE Ratio | 23.49 |
| Target Price | 53.0313 |
| Dividend Yield | 1.4% |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AFX.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
